摘要
上皮性卵巢癌(后文简称卵巢癌)是最致命的妇科恶性肿瘤。铂类化疗仍是卵巢癌的标准治疗方案。虽然多数卵巢癌患者对铂类药物治疗有反应,但复发性卵巢癌铂类药物耐药不可避免。铂耐药复发性卵巢癌预后差,治疗选择少,疗效有限,开发寻求新的治疗策略迫在眉睫。本文汇总并探讨铂耐药复发性卵巢癌临床治疗的现状和新型疗法的临床进展。
Epithelial ovarian cancer,abbreviated as ovarian cancer,is the deadliest gynecologic malignancy,and platinum-based chemotherapy remains the standard treatment option for ovarian cancer.Although most patients respond to platinum-based drug therapy,platinum resistance in recurrent ovarian cancer is inevitable.With poor prognosis,few treatment options,and limited efficacy in platinum-resistant recurrent ovarian cancer,the development of new therapeutic strategies is imminent.This article summarizes and discusses the current status of clinical treatment for platinum-resistant recurrent ovarian cancer and clinical advances in novel therapies.
作者
孙芳颖
杨建华
Sun Fangying;Yang Jianhua(School of Medicine,Shaoxing University,Shaoxing 312000,China;Department of Obstetrics and Gynecology,Sir Run Run Shaw Hospital,Zhejiang University,Hangzhou 310000,China)
出处
《实用肿瘤杂志》
CAS
2024年第5期419-424,共6页
Journal of Practical Oncology
关键词
上皮性卵巢癌
复发
铂耐药
治疗
epithelial ovarian cancer
recurrence
platinum-resistant
treatment
